ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal ...
Gout is a type of arthritis characterized by severe pain, swelling, and stiffness in a joint, most often the big toe. It ...
A recent study presented by Orit Cohen Barak in the ACR Convergence 2024 showed that with the extra advantage of a ...
Atom Therapeutics partners with China Medical System to commercialize lingdolinurad for gout and hyperuricemia in China, Hong ...
Using urate-lowering therapy to reach target urate levels appears safe in patients with chronic kidney disease (CKD).
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today ...
China Medical System (CHSYF) entered into an Exclusive Commercialization Agreement with Atom Therapeutics of class 1 innovative drug ABP-671 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback